Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs
Since the introduction of selective cyclooxygenase-2 inhibitors (coxibs), there has been an ongoing discussion about the cardiovascular (CV) safety of coxibs and the traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Available data about the CV safety of NSAIDs come mostly from meta-analyses and a few clinical trials. Current evidence suggests that NSAIDs may increase the risk of CV events. Naproxen might be associated with lower risk, but available data are not conclusive. Recent recommendations on the treatment of patients with NSAIDs favor the use of naproxen in patients with increased CV risk. Therefore, this review focuses on data about naproxen and examines CV risk with ibuprofen and non-naproxen NSAIDs. In addition, data about CV safety of paracetamol (acetaminophen) are presented.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 13.Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clinical Trials 2006, 1:e33.Google Scholar
- 15.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71–86.Google Scholar
- 21.Chan FK, Abraham NS, Scheiman JM, Laine L: Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Antiplatelet Agents. Am J Gastroenterol 2008 (in press).Google Scholar
- 24.Sudano I, Flammer AJ, Periat D, et al.: Paracetamol increases 24-hour blood pressure in patients with stable coronary artery disease. Paper presented at 18th Scientific Meeting of the European Society of Hypertension/22nd Scientific Meeting of the International Society of Hypertension. Berlin, Germany, 2008.Google Scholar